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OBJECTIVE—Oxyntomodulin (OXM) is a glucagon-like peptide
1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual
agonist peptide that reduces body weight in obese subjects
through increased energy expenditure and decreased energy
intake. The metabolic effects of OXM have been attributed
primarily to GLP1R agonism. We examined whether a long acting
GLP1R/GCGR dual agonist peptide exerts metabolic effects in
diet-induced obese mice that are distinct from those obtained
with a GLP1R-selective agonist.
RESEARCH DESIGN AND METHODS—We developed a pro-
tease-resistant dual GLP1R/GCGR agonist, DualAG, and a corre-
sponding GLP1R-selective agonist, GLPAG, matched for GLP1R
agonist potency and pharmacokinetics. The metabolic effects of
these two peptides with respect to weight loss, caloric reduction,
glucose control, and lipid lowering, were compared upon chronic
dosing in diet-induced obese (DIO) mice. Acute studies in DIO
mice revealed metabolic pathways that were modulated indepen-
dent of weight loss. Studies in Glp1r
/ and Gcgr
/ mice
enabled delineation of the contribution of GLP1R versus GCGR
activation to the pharmacology of DualAG.
RESULTS—Peptide DualAG exhibits superior weight loss, lipid-
lowering activity, and antihyperglycemic efﬁcacy comparable to
GLPAG. Improvements in plasma metabolic parameters includ-
ing insulin, leptin, and adiponectin were more pronounced upon
chronic treatment with DualAG than with GLPAG. Dual receptor
agonism also increased fatty acid oxidation and reduced hepatic
steatosis in DIO mice. The antiobesity effects of DualAG require
activation of both GLP1R and GCGR.
CONCLUSIONS—Sustained GLP1R/GCGR dual agonism re-
verses obesity in DIO mice and is a novel therapeutic approach to
the treatment of obesity. Diabetes 58:2258–2266, 2009
O
besity is an important risk factor for type 2
diabetes, and 90% of patients with type 2
diabetes are overweight or obese (1). Among
new therapies for type 2 diabetes, peptidyl
mimetics of the gut-derived incretin hormone glucagon-
like peptide 1 (GLP-1) stimulate insulin biosynthesis and
secretion in a glucose-dependent manner (2,3) and cause
modest weight loss in type 2 diabetic patients. The
glucose-lowering and antiobesity effects of incretin-based
therapies for type 2 diabetes have prompted evaluation of
the therapeutic potential of other glucagon-family pep-
tides, in particular oxyntomodulin (OXM). The OXM
peptide is generated by post-translational processing of
preproglucagon in the gut and is secreted postprandially
from L-cells of the jejuno-ileum together with other pre-
proglucagon-derived peptides including GLP-1 (4,5). In
rodents, OXM reduces food intake and body weight,
increases energy expenditure, and improves glucose me-
tabolism (6–8). A 4-week clinical study in obese subjects
demonstrated that repeated subcutaneous administration
of OXM was well tolerated and caused signiﬁcant weight
loss with a concomitant reduction in food intake (9). An
increase in activity-related energy expenditure was also
noted in a separate study involving short-term treatment
with the peptide (10).
OXM activates both, the GLP-1 receptor (GLP1R) and
glucagon receptor (GCGR) in vitro, albeit with 10- to
100-fold reduced potency compared with the cognate
ligands GLP-1 and glucagon, respectively (11–13). It has
been proposed that OXM modulates glucose and energy
homeostasis solely by GLP1R agonism, because its acute
metabolic effects in rodents are abolished by coadminis-
tration of the GLP1R antagonist exendin(9–39) and are not
observed in Glp1r
/ mice (7,8,14,15). Other aspects of
OXM pharmacology, however, such as protective effects
on murine islets and inhibition of gastric acid secretion
appear to be independent of GLP1R signaling (14). In
addition, pharmacological activation of GCGR by gluca-
gon, a master regulator of fasting metabolism (16), de-
creases food intake in rodents and humans (17–19),
suggesting a potential role for GCGR signaling in the
pharmacology of OXM. Because both OXM and GLP-1 are
labile in vivo (T1/2 12 min and 2–3 min, respectively)
(20,21) and are substrates for the cell surface protease
dipeptidyl peptidase 4 (DPP-4) (22), we developed two
long-acting DPP-4–resistant OXM analogs as pharmaco-
logical agents to better investigate the differential pharma-
cology and therapeutic potential of dual GLP1R/GCGR
agonism versus GLP1R-selective agonism. Peptide DualAG
exhibits in vitro GLP1R and GCGR agonist potency com-
parable to that of native OXM and is conjugated to
cholesterol via a Cys sidechain at the C-terminus for
improved pharmacokinetics. Peptide GLPAG differs from
DualAG by only one residue (Gln
33Glu) and is an equi-
potent GLP1R agonist, but has no signiﬁcant GCGR ago-
nist or antagonist activity in vitro. The objective of this
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cies and pharmacokinetics of peptides DualAG and GL-
PAG in comparing the metabolic effects and therapeutic
potential of a dual GLP1R/GCGR agonist with a GLP1R-
selective agonist in a mouse model of obesity.
RESEARCH DESIGN AND METHODS
Experiments were performed in lean and diet-induced obese (DIO) C57BL/6
mice and in weight- and sex-matched Gcgr
/ (23), Glp1r
/ (24), or lean
C57BL/6 control mice. All mice were obtained from Taconic Farms (German-
town, NY) and were maintained on either standard rat diet (Teklad 7012;
Harlan Teklad) or high-fat diet (D12492: 60% kcal from fat; Research Diets) in
a 12-h light/12-h dark cycle (light: 3:00 A.M. to 3:00 P.M.). Animal protocols used
in these studies were approved by the Merck Research Laboratories Institu-
tional Animal Care and Use Committee (Rahway, NJ).
Peptides. The free thiol-containing peptide precursors of DualAG and GLPAG
were synthesized by standard solid-phase peptide synthesis using Fmoc/t-Bu
chemistry. Peptides were synthesized by reverse-phase HPLC using water/
acetonitrile (0.1% triﬂuoroacetic acid) gradients. Cholesterol-peptide conju-
gates were synthesized by reaction of the thiol-containing peptide precursors
with cholest-5-en-3-yl-1-bromo-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oate,
which was previously assembled by standard solution chemistry. The peptide
conjugates were puriﬁed by reverse-phase chromatography using water/
acetonitrile (0.2% acetic acid) gradients. Puriﬁed peptides were characterized
by electrospray MS on a Micromass LCZ platform spectrometer.
Determination of murine GLP1R and GCGR agonist potency. In vitro
agonist potency of peptides was determined in Chinese hamster ovary (CHO)
cells stably expressing murine GLP1R or murine GCGR using the Cisbio cAMP
Dynamic 2 assay. Peptides were diluted in assay buffer and incubated with
cells in the presence of 20% mouse plasma. The assay was terminated with the
addition of the Cisbio detection reagents as per the manufacturer’s instruc-
tions. cAMP was detected by a decrease in time-resolved ﬂuorescence energy
transfer (TR-FRET) using an EnVision platereader (PerkinElmer).
Ex vivo liver glycogenolysis assay. The ability of DualAG and GLPAG to
stimulate glycogen breakdown was evaluated ex vivo in perfused livers
harvested from C57BL/6 mice using a
13C-nuclear magnetic resonance (NMR)-
based assay as previously described (25).
Measurement of plasma peptide exposures at the end of the chronic
study. DIO mice, 23 weeks old and maintained for 16 weeks on a high-fat diet,
were anesthetized with isoﬂuorane, and blood was collected by cardiocentesis
into EDTA-coated microtainer tubes containing DPP-4 inhibitor and aprotinin.
The in vitro cell-based cAMP bio-assay for determining GLP1R agonist
potency was used with CHO cells stably transfected with human GLP1R to
determine peptide concentrations by comparing the degree of cAMP accumu-
lation in plasma samples from treated animals against a cAMP standard curve
generated by spiking peptide standards into mouse plasma.
Single-dose studies in DIO mice. Weight- (45 g) and age-matched DIO
mice (23 weeks old) were subcutaneously injected at 9:00 A.M. with vehicle,
DualAG, or GLPAG at a dose of 191 nmol/kg. Food was removed, and 6 h later
(3:00 P.M., Tmax for GLPAG and DualAG) the animals were killed for
collection of plasma and tissue samples, which were immediately stored at
80°C.
RNA preparation and quantitative RT-PCR. RNA was isolated from
tissues using Ultraspec Total RNA Isolation Reagent (Biotecx Laboratories).
The resulting total RNA was subjected to DNAse treatment using RNAse-
freeDNAse (Qiagen). After reverse transcription of the RNA to generate
cDNA, quantitative RT-PCR was performed with TaqMan PCR Reagent using
the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Taq-
man probes were purchased from Applied Biosystems: ChREBP
(Mm00498811_m1), Cpt1a (Mm00550438_m1), Fgf21 (Mm00840165_g1), Ldlr
(Mm00440169_m1), Pck1 (Mm00440636_m1), Pgc-1 (Mm00447183_m1). Ex-
pression was normalized to the copy number for -actin (Actb).
Quantitation of malonyl-CoA and acetyl-CoA. Mouse liver samples (100
mg) were homogenized in 1 ml of 10% sulfosalicylic acid, 10 mmol/l dithio-
threitol. The samples were spun at 15,000  g, and the supernatant was
analyzed by LC/MS after 10-fold dilution using an Agilent 1100 series capillary
pump interfaced to an LTQ ion trap mass spectrometer (Thermo Scientiﬁc).
The assay was adapted from Minkler et al. (26).
Chronic dosing of DualAG and GLPAG in DIO mice. Male DIO mice (23
weeks old, n  8/dosing group, maintained for 16 weeks on a high-fat diet),
were acclimated to nonspeciﬁc stress for 10 days before the onset of the
chronic dosing study. DualAG (1.9 mol/kg), GLPAG (1.9 mol/kg), or vehicle
(water) was injected subcutaneously every other day for 2 weeks. Body
weight and food intake were measured daily. An intraperitoneal glucose
tolerance test (IPGTT, 1.5 g/kg dextrose challenge) was performed on day 13
of the chronic study at 10:00 A.M. Whole body composition analysis of
conscious mice was conducted before (day 0) and at the conclusion of the
study by EchoMRI (Echo Medical Systems). Plasma samples for measurement
of terminal plasma concentration of active GLPAG and DualAG were obtained
18 h after the last injection by cardiocentesis.
Food intake and body weight studies in Glp1r
/ and Gcgr
/ mice.
Single-caged weight-matched (30 g) wild-type (n  24), Glp1r
/ (n  24),
and Gcgr
/ (n  21) mice were injected daily (subcutaneously) with vehicle,
DualAG (1.9 mol/kg), or GLPAG (1.9 mol/kg), 30 min before the onset of the
dark cycle for 5 days. Food intake and body weight were recorded daily for the
duration of the study.
Histology. Liver histology was performed as described elsewhere (27).
Biochemical analyses. Insulin and leptin levels in plasma were measured by
ELISA (Linco/Millipore). Plasma free fatty acids and ketone bodies were
measured using commercially available enzyme-coupled spectrophotometric
assays (Wako Chemicals). Plasma triglyceride and total cholesterol were
determined using an Olympus AU400e Bioanalyzer. Adiponectin was mea-
sured using a mouse adiponectin RIA kit (Linco/Millipore). Blood glucose
levels were measured using a OneTouch glucometer (Ultra LifeScan).
Statistics. All data are presented as means  SE. Comparisons among groups
were made using ANOVA or unpaired Student’s t test, as appropriate. P 	 0.05
was regarded as statistically signiﬁcant.
RESULTS
Development of long-acting GLP1R/GCGR DualAG
and GLP1R-selective agonist (GLPAG) peptides. As
summarized in Fig. 1A, glucagon and OXM, the only
members of the glucagon superfamily that activate GCGR,
incorporate a neutral polar residue at position three
(glutamine, Q). In contrast, GLP-1 and the GLP-1 mimetic
exendin-4 exhibit no signiﬁcant GCGR agonist activity and
incorporate an acidic residue at this position (glutamate,
E), which decreases binding afﬁnity to GCGR (28,29).
Peptide DualAG is a long-acting analog of OXM with a
Ser
23DSer substitution for resistance to DPP-4 cleavage.
A Gln
33Glu substitution was introduced in DualAG to
generate analog GLPAG. As illustrated in Fig. 1A, a cho-
lesterol moiety was conjugated to the thiol side chain of a
Cys residue appended to the C-terminus of each OXM
analog to improve pharmacokinetics and enhance meta-
bolic stability via plasma lipid and protein binding. The
insertion of a short polyethylene glycol spacer between
the cholesterol moiety and the peptides ameliorated a
decrease in potency of the conjugates in the presence of
plasma that occurs because of protein/lipid binding. A
more complete description of the discovery and develop-
ment of these peptides will be provided elsewhere (Bian-
chi et al., manuscript in preparation).
Consistent with a previous report of DSer
2-glucagon
being resistant to DPP-4 cleavage (30), peptides DualAG
and GLPAG exhibited no loss of in vitro potency after
overnight incubation at 37°C with human recombinant
soluble DPP-4 (31). Protease resistance of the peptides
was further supported by pharmacokinetics data. The Tmax
(time corresponding to peak plasma concentration post-
dose) for DualAG administered subcutaneously in lean
C57Bl/6 mice at a dose of 3 mg/kg was 5 h, as determined
using a bioassay for GLP1R agonism. The corresponding in
vivo half-life (T1/2) for circulating active peptide was 1.7 h
(compared with T1/2 8–12 min for native OXM) (32).
Peptide GLP1AG exhibited comparable in vivo stability to
DualAG as reﬂected by comparable plasma concentrations
of bioactive peptides measured at 24 h postdose in mice
(Fig. 2B, inset).
As summarized in Fig. 1B, DualAG is a full agonist of
both, mGLP1R (EC50, cAMP  3.4 nmol/l) and mGCGR
(EC50, cAMP  1.5 nmol/l) and is comparable in potency to
OXM in vitro, using a cell-based assay that measures cAMP
A. POCAI AND ASSOCIATES
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respective recombinant murine receptor. GLPAG is an
equipotent mGLP1R agonist (EC50, cAMP  1.7 nmol/l),
with at least 100-fold reduced mGCGR agonist potency
compared with DualAG. The GCGR receptor selectivity of
these long-acting peptides was further conﬁrmed using an
ex vivo assay that monitors glycogenesis and glycogenol-
ysis in a perfused mouse liver (25). Brieﬂy, a
13C-NMR
visible pool of glycogen was created by perfusion of the
gluconeogenic substrate [2-
13C] pyruvate and liver glyco-
gen was monitored in real time via the C1 resonance of the
glucosyl units in the glycogen chain. DualAG or GLPAG
was subsequently infused, and loss of label from glycogen
(glycogenolysis) was monitored by
13C-NMR to assess
GCGR activation (supplementary Fig. 1A and B, available
in an online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0278/DC1). Peptide DualAG in-
duced full glycogenolysis at a perfusate concentration of
1 nmol/l (EC50, glyco 0.5 nmol/l), which compares
favorably with its in vitro potency against mGCGR. In
contrast, a much higher peptide perfusate concentration
(300 nmol/l) was required for maximal stimulation of
glycogenolysis by GLPAG (EC50, glyco 208 nmol/l), con-
sistent with 
100-fold reduced agonist potency against
mGCGR. Peptides DualAG and GLPAG showed no antag-
onist activity at GCGR and were inactive at other recep-
tors of the glucagon-secretin family (PAC1, VPAC1,
VPAC2, and GIPR, EC50, cAMP 
10 mol/l).
DualAG reverses obesity and improves glucose me-
tabolism in mice. DIO mice were injected subcutane-
ously with DualAG or GLPAG (1.9 mol/kg) in a 14-day
chronic study (Fig. 2A). Although peak plasma peptide
concentrations (Cmax) were achieved 5 h after subcuta-
neous injection and the plasma T1/2 suggests daily dosing
as optimal, both peptides were injected every other day to
minimize the stress caused by frequent injections. DualAG
exhibited superior weight loss efﬁcacy compared with
GLPAG at day 14 (25 and 12% decrease in body weight,
respectively, relative to vehicle-treated mice, Fig. 2B). As
noted earlier, plasma peptide exposures measured at 24 h
after the last injection were similar for DualAG and
GLPAG (Fig. 2B, inset), conﬁrming the matched pharma-
cokinetics of the two peptides. As depicted in Fig. 2C,
cumulative food intake was reduced to a greater extent
with the DualAG than with GLPAG (30 and 12% reduction,
respectively, relative to vehicle). Body composition anal-
ysis conﬁrmed that the decrease in body weight was
primarily accounted for by a proportional decrease in fat
mass (Fig. 2D). An IPGTT performed on day 13 (20 h after
the last injection) revealed that glucose tolerance was
signiﬁcantly and comparably improved in both treatment
groups (Fig. 2E). Furthermore, basal blood glucose levels
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FIG. 1. Sequence alignment and receptor agonist potencies of OXM and related peptides. A: Sequence alignment of OXM, exendin-4, and related
glucagon superfamily peptides including the long acting OXM analogs DualAG and GLPAG. Conserved residues are highlighted. Gln
3 is important
for GCGR agonist activity. DualAG and GLPAG incorporate a DSer
2 (S) substitution that confers resistance to DPP-4. The cholesterol moiety
(chol) at the C-terminus of these peptides enhances metabolic stability and receptor afﬁnity, and the intervening polyethylene glycol spacer
minimizes the loss in agonist potency because of plasma protein/lipid binding. B: In vitro receptor agonist potencies (cAMP release) against
mGLP1R and mGCGR and ED50 (nM) in the ex vivo mouse liver glycogenolysis assay (mGlyco). The Gln
33 Glu substitution in GLPAG reduces
GCGR agonist activity 120- to 400-fold compared with DualAG.
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(Fig. 2E, t  0 measurement predextrose challenge in the
IPGTT). Several other metabolic parameters in plasma
were also improved by chronic treatment with the pep-
tides (Table 1). Increases in adiponectin and decreases in
leptin and insulin levels correlated with the decreased
adiposity observed at the end of the study in each treat-
ment group. Reduced cholesterol and triglyceride levels,
increased ketone bodies, and decreased hepatic steatosis
(Fig. 3) relative to vehicle treatment were also noted,
especially for animals treated with DualAG.
To identify metabolic pathways acutely altered by Du-
alAG and GLPAG before any signiﬁcant weight loss, age-
and weight-matched DIO mice were injected with vehicle,
DualAG, or GLPAG (191 nmol/kg subcutaneously each
peptide) and killed 6 h later to collect plasma for metab-
olites and liver tissue samples for gene expression analy-
sis. Despite the acute treatment, decreased plasma
triglycerides and increased ketone bodies were detected
albeit only in animals treated with the dual agonist (sup-
plementary Fig. 2). Increased expression of the gluconeo-
genic genes Pck1, Pgc1, and Pdha1 was observed with
DualAG treatment, but not with GLPAG or vehicle (Fig.
4A–C). Liver pools of acetyl-CoA, the main product of
pyruvate decarboxylation, and malonyl-CoA were de-
creased by DualAG (Fig. 4D and E). In addition, DualAG
caused a signiﬁcant upregulation of genes that induce fatty
acid oxidation (FAO) in the liver, including Fgf21 and
Cpt1a (Fig. 4F and G), and the downregulation of lipo-
genic genes such as ChREBP (Fig. 4H). A robust (15-
fold) upregulation of Ldlr by DualAG (Fig. 4I) was also
noted in the context of reduced cholesterol levels previ-
ously observed with chronic treatment (Table 1).
Metabolic effects of DualAG and GLPAG in Glp1r
/
and Gcgr
/ mice. To provide mechanistic insight into
the relative contributions of each target receptor to the
metabolic effects of the long-acting peptides, we compared
the effect of repeat administrations of DualAG and GLPAG
2
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FIG. 2. Superior efﬁcacy of a long-acting dual GLP1/GCGR agonist in reducing body weight in DIO mice. A: Study protocol for chronic dosing
of animals with vehicle or peptides DualAG and GLPAG (1.9 mol/kg subcutaneously, every other day). B: Cumulative changes in body
weight. Plasma exposures of each peptide measured at the end of the study were comparable (inset). C: Cumulative food intake and (D)
body composition changes for each treatment group. E: IPGTT conducted on day 13 of the study. *P < 0.05, DualAG and GLPAG versus
vehicle; ^P < 0.05, DualAG versus GLPAG.
A. POCAI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2261(1.9 mol/kg subcutaneously) on body weight and food
intake in wild-type mice with that in animals lacking either
GLP1R (Glp1r
/) or GCGR (Gcgr
/). Because both
receptor knockout mouse lines are resistant to diet-
induced obesity, weight-matched lean mice were used in
the study. Both peptides signiﬁcantly reduced cumulative
food intake and body weight in wild-type mice. As ob-
served previously, DualAG treatment effected superior
body weight loss in wild-type mice compared with animals
treated with GLPAG (Fig. 5). In mice lacking either GLP1R
or GCGR, however, the efﬁcacy of DualAG was sustained
but partially attenuated compared with the weight loss
achieved in wild-type mice. These results implicate both
GLP1R and GCGR activation in the mechanism of action of
DualAG. The weight loss efﬁcacy of GLPAG in Gcgr
/
mice was comparable to the attenuated body weight
effects of DualAG in these animals and was completely
abolished in Glp1r
/ mice, conﬁrming the GLP1R selec-
tivity of this peptide.
DISCUSSION
Herein, we compare the antiobesity effects of a long-acting
dual GLP-1/glucagon agonist (DualAG) with those of a
long-acting GLP1R selective agonist (GLPAG) in a mouse
model of obesity. To avoid confounding effects in these
studies, a speciﬁc effort was made to match the pharma-
cokinetics, GLP1R agonist potencies, and plasma expo-
sures of the two peptides during chronic dosing studies.
Long-acting peptides DualAG and GLPAG lowered blood
glucose, reduced food intake, and decreased body weight
in DIO mice. We report for the ﬁrst time that chronic
treatment with a dual GLP1R/GCGR agonist compared
with a GLP1R selective agonist causes superior weight
loss and lipid lowering in DIO mice, without causing
hyperglycemia. Instead, ambient glucose levels were nor-
malized by both peptides, and glucose tolerance was
comparably improved in both groups as measured in an
IPGTT conducted at the end of the study. Of note, im-
provements in metabolic parameters such as plasma insu-
lin, leptin, and adiponectin were typically more
pronounced upon chronic treatment with DualAG than
with GLPAG, consistent with the increased weight loss
efﬁcacy of the dual agonist.
To evaluate the contributions of GLP1R versus GCGR
agonism to the observed pharmacology of the long-acting
peptides, we evaluated the metabolic effects of repeat
dosing with DualAG and GLPAG in Glp1r
/ and Gcgr
/
mice. Our studies clearly establish the importance of dual
GLP1R/GCGR agonism in the increased weight loss efﬁ-
TABLE 1
Chronic treatment of DIO mice with DualAG and GLPAG: plasma
parameters measured at the end of the 14-day study
Vehicle
DualAG GLPAG
1.9 mol 
kg
1  day
1
1.9 mol 
kg
1  day
1
N 67 7
Insulin (ng/ml) 13.2  0.7 4.0  0.2*† 7.8  1.1*
Leptin (ng/ml) 32  41 4  1*† 19  1*
Adiponectin
(g/ml) 15  12 8  2*† 20  1*
Fatty free acids
(mM) 0.2  0.0 0.4  0.1 0.3  0.0
Cholesterol 153  67 6  7*† 107  5*
Triglycerides
(mg/dl) 68  84 4  5* 47  6*
-hydroxybutyrate
(mg/dl) 4.1  0.3 9.3  0.9* 7.2  0.4*
Data are means  SE. *P 	 0.05 vs. vehicle; †P 	 0.05 DualAG vs.
GLPAG.
A
B
C
FIG. 3. Histological analysis (photomicrographs) of lipid accumulation
in liver obtained from DIO mice treated chronically with DualAG and
GLPAG. Hematoxylin-eosin stain of hepatic histological sections ob-
tained from animals treated with vehicle (A), DualAG (B), and GLPAG
(C). Magniﬁcation 300.
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with DualAG treatment in both Glp1r
/ and Gcgr
/
mice, although efﬁcacy was reduced compared with body
weight effects observed in weight-matched wild-type mice.
In contrast, the metabolic effects of GLPAG were com-
pletely ablated in Glp1r
/ mice, conﬁrming its GLP1R
selective effects.
A uniﬁed hypothesis for the mechanism of action of
peptide DualAG is illustrated in Fig. 5G. Under conditions
of fasting metabolism, GCGR signaling pharmacologically
accentuates the catabolic aspects of metabolism that favor
weight loss. DualAG activates GCGR in the liver, rapidly
upregulating key gluconeogenic genes. However, in-
creased GLP1R signaling in the postprandial state is
sufﬁcient to improve glucose tolerance with a dual agonist
peptide, as has been reported with native OXM in mice
(6,14). Our studies also conﬁrm the contribution of GLP1R
agonism to the chronic antiobesity effect of DualAG,
which is driven primarily by a reduction in adiposity. As
illustrated in Fig. 5G, DualAG modulates metabolic path-
ways that decrease acetyl-CoA and malonyl-CoA pools in
the liver, increase ketogenesis, and decrease plasma lipids.
Hormone-sensitive lipase mRNA, which is downregulated
in animal models of obesity (33) and in obese humans
(34,35), is signiﬁcantly upregulated in adipose tissue ob-
tained from DIO mice treated with DualAG (data not
shown). Although the role of glucagon in fat cell metabo-
lism in humans is unclear, pharmacological activation of
GCGR in adipose tissue may activate hormone-sensitive
lipase, resulting in an increased free fatty acid pool
available for -oxidation (36). Our data suggest that FAO
is acutely upregulated in rodents by GLP1R/GCGR dual
agonism before any weight loss. The observed upregula-
tion of liver Fgf21 by DualAG may also contribute to the
action of a dual GLP1R/GCGR agonist because pharmaco-
logical levels of FGF21 stimulate hepatic FAO and in-
crease energy expenditure (37,38).
The increased weight loss efﬁcacy of DualAG compared
with GLPAG is consistent with previous research on the
pharmacology of glucagon. The hormone has been re-
ported to decrease total cholesterol in rats and to cause a
greater reduction in body weight compared with a pair-fed
group of animals because of both reduced food intake and
increased energy expenditure (19). Conversely, Langhans
et al. (39) showed that intraperitoneal injections of anti-
glucagon antibodies in food-deprived rats increased meal
size and duration. Furthermore, chronic administration of
glucagon in humans has been reported to increase satiety
and decrease hunger scores (17,18). Of note, however,
GCGR-selective agonism is typically associated with the
risk of hyperglycemia because elevation of endogenous
glucagon levels and concomitant reduction in insulin
levels/action are accepted as key players in the pathogen-
esis of diabetic hyperglycemia (40). According to this
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results in excessive hepatic glucose production, which is
not balanced by glucose utilization under conditions of
hypoinsulinemia and insulin resistance. Indeed, the devel-
opment of GCGR antagonists for the treatment of type 2
diabetes is being actively pursued (25,41–44) because
these agents act toward restoring normal GCGR tone.
Distinct from the demonstrated imbalance in endogenous
hormonal action that characterizes the pathology of type 2
diabetes, however, we now report for the ﬁrst time that
concomitant activation of GLP1R in rodents mitigates the
metabolic risks associated with GCGR activation while
leveraging the beneﬁcial pharmacological effects of acti-
vating each receptor, including enhanced weight loss
efﬁcacy, antihyperglycemic activity, and lipid-lowering ef-
fects. Our hypothesis is that pharmacological GLP1R ago-
nism results in enhanced glucose-dependent insulin
secretion, which enhances glucose disposal and provides
sufﬁcient anabolic tone to balance the glucoregulatory and
catabolic effects of concomitant GCGR agonism. Hence,
the GLP1R/GCGR dual agonist peptide DualAG mediates
safe and effective weight loss and improves glucose toler-
ance in rodents without causing hyperglycemia or ca-
chexia. Whether the observed rodent pharmacology is
predictive of clinical effects with a long-acting dual agonist
peptide remains to be determined, although the weight
loss obtained with native OXM in overweight subjects is
encouraging (9), given the rapid clearance of this peptide.
In conclusion, we propose that long-acting GLP1R/GCGR
dual agonists such as peptide DualAG represent novel
pharmaceutical agents for the treatment of obesity.
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